By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genzyme Corporation 

500 Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-252-7500 Fax: 617-252-7600


About Genzyme

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.

Learn more at

Follow our jobs on Twitter

Follow us on LinkedIn

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Key Statistics

Ownership: Subsidiary

Web Site: Sanofi Genzyme
Symbol: SNY



Medtronic  Cardiac Cell Therapy

Cambridge Antibody Technology  Antibodies against TGF-ß

Dyax  Hereditary Angioedema


Company News
Sanofi Genzyme (SNY) Release: Prince Edward Island Includes LEMTRADA (Alemtuzumab) On Provincial Drug Program For Eligible Patients 8/2/2017 11:14:56 AM
Alnylam (ALNY) And Sanofi Genzyme (SNY) Report Positive Results From Ongoing Phase II Open-Label Extension Study With Investigational Rnai Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors 7/10/2017 8:28:52 AM
Alnylam (ALNY) And Sanofi Genzyme (SNY) Initiate ATLAS Phase III Program With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors 7/7/2017 6:30:37 AM
Alnylam (ALNY) And Sanofi Genzyme (SNY) To Present New Clinical Trial Results At The International Society Of Thrombosis And Haemostasis (ISTH) Congress 6/27/2017 7:20:58 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
Another Top Sanofi Genzyme (SNY) Exec Jumps Ship 5/11/2017 6:04:52 AM
Sanofi Genzyme (SNY) Announces Approval Of Cerdelga (Eliglustat Capsules) By Health Canada For Rare Genetic Condition 5/1/2017 6:24:38 AM
New Investigational Data On Six-Year Efficacy Of Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented At American Academy of Neurology 4/25/2017 8:18:58 AM
New Data Suggest Positive Effects Of Sanofi Genzyme (SNY)’s Aubagio (Teriflunomide) On Cortical Gray Matter Atrophy 4/25/2017 8:06:20 AM
Rhythm Appoints Head Of Sanofi Genzyme (SNY), Dr. David Meeker, As Chairman Of Board Of Directors 4/11/2017 9:12:09 AM